Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowRoche Diagnostics Corp. is mulling a sale of its blood-glucose meter business, according to a Reuters report, a move that would cast uncertainty over the nearly 1,000 people working for its diabetes business in Indianapolis.
Reuters reported the potential sale on Wednesday, citing three people familiar with the matter. A Roche spokesman declined to comment to IBJ.
The entire blood-glucose meter industry is facing a huge hit to sales on July 1, when the federal Medicare program will start a competitive bidding program for blood-glucose testing strips and supplies, which could cut its payments as much as 72 percent. The Medicare program for seniors is the largest health insurance program in the United States.
The Medicare cuts will directly affect a Roche test-strip plant in Indianapolis, which employs more than 150 workers and churns out more than 2 billion strips per year.
Two years ago, Roche decided to spend $37 million to expand its test strip plant in Indianapolis, in part to keep up with growing global demand.
But, last year, reimbursement cuts, as well as stiff price competition from generic makers of blood-glucose meters, forced Roche to restructure its diabetes business. The company cut 100 diabetes care positions between its two main locations in Indianapolis and Mannheim, Germany.
“There are lots of players here that are discussing either pulling out, consolidating or just riding it through,” wrote Kelly Close and Kira Maker, two diabetes analysts at San Francisco-based market research firm Close Concerns Inc., in an April report.
Roche Diagnostics’ North American blood-glucose monitor sales declined 6 percent last year, to $598 million, according to Close Concerns. Close Concerns predicts Roche's blood-glucose sales in North America will swoon this year by 23 percent, to $463 million.
Roche's blood-glucose monitoring business has also been suffering globally. Sales declined 10 percent last year, to $2.5 billion, and Close Concerns predicts another 8-percent dropoff this year.
Roche isn't alone. In the United States, blood-glucose monitoring has been a declining business since sales peaked in 2007 at nearly $3 billion. But this year will be especially bad, with an estimated 19-percent decline in sales, according to Close Concerns. Globally, sales of blood-glucose monitors peaked in 2011, but then fell 5 percent last year and are expected to decline another 11 percent this year.
Reuters' sources said there are only a few possible buyers of Roche’s blood-glucose meter business, including Minnesota-based Medtronic Inc. and New Jersey-based Johnson & Johnson.
A purchase by one of those companies could preserve Roche’s diabetes operations in Indianapolis, but it could also lead to their relocation.
However, a sale may not actually happen, Reuters noted. Last year, Germany-based Bayer AG attempted to sell its blood glucose meter business for about $1.5 billion, but failed to find a buyer.
Please enable JavaScript to view this content.